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Coronavirus disease (COVID-19), caused by 
SARS-CoV-2, originated as a global pandemic and 
has had a major impact on Europe. Spain, with 
more than 1,600,000 confirmed cases and a fatal-
ity rate of approximately 2.75%, is one of the most 
affected countries to date [1]. A high prevalence of 
cardiovascular (CV) comorbidity, consisting mostly 
of coronary artery disease (CAD) and arrhythmias, 
has been reported among the deceased [2, 3].
Additionally, a wide variety of CV manifesta-
tions has been described in COVID-19 patients, 
either as a result of the invasion of endothelial cells 
and myocardiocytes (carriers of the ACE recep-
tor on their membrane) by the SARS-CoV-2, as 
a consequence of the cytokine storm [2] or due to 
impaired microcirculatory function [4].
The purpose herein, is to describe the preva-
lence of CV comorbidity in the patients who died 
on the hospital wards of a Spanish tertiary hospital 
and to examine the differences in baseline charac-
teristics, laboratory findings, days until death and 
treatment received compared to those who died 
without these comorbidities.
All patients infected with SARS-CoV-2 who 
died in the hospital wards between March 9 and 
April 16, 2020, were consecutively included. Those 
who died in the intensive care unit were ex-
cluded on the grounds that their evolution and 
potential causes of morbidity and death might 
be different. Clinical and analytical variables 
were collected. Myocardial injury, measured as 
maximum elevation of troponin I, was analyzed. 
A patient who suffered an acute coronary syndrome 
with ST-segment elevation due to late thrombosis 
from a previously implanted stent was excluded 
from the analysis for this variable. The CURB-65 
scale was used to stratify the risk at admission [5].
A total of 324 deceased patients were included, 
with an age of 81 ± 10 years, 44% of them were 
women, and a high prevalence of hypertension 
(78%), dyslipidemia (58%) and diabetes (34%). 
Sixty-two (19%) had a history of atrial fibrillation 
(AF) and 40 (12%) of previous CAD. 
Patients with AF vs. patients without AF were 
older (85 ± 6 vs. 81 ± 10 years, p = 0.0006). They 
presented with a higher prevalence of hyperten-
sion (90% vs. 75%, p = 0.012) and chronic kidney 
disease (53% vs. 37%, p = 0.022) (Table 1).
Patients with CAD vs. patients without CAD, 
in turn, exhibited a higher prevalence of hyperten-
sion (95% vs. 76%, p = 0.006), dyslipidemia (83% 
vs. 54%, p = 0.001) and ventricular systolic dys-
function (55% vs. 23%, p < 0.001). No differences 
were found in the presence of other comorbidities.
Most patients (88%) had a CURB-65 score 
of 2 or higher on admission, with no differences 
noted between those with and without CV comor-
bidity. 
Fifty-two percent of the patients who present-
ed with maximum troponin values above the limit of 
normality (0.05 ng/mL) and 22% presented values 
higher than 5 times that limit. No differences were 
found in the presence of troponin elevation or in 
its quantitative value in patients with AF or CAD.
D-dimer elevation was present in 77% of 
patients, being less frequent in those with AF 
(80% vs. 63%, p = 0.016), irrespective of the an-
ticoagulation received. No differences were found 
regarding the presence of lymphopenia, lactate 
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Regarding treatment, patients with AF more 
frequently received anticoagulation at full doses 
compared to patients without AF (61% vs. 13%, 
p < 0.001). However, the proportion of patients 
within this group without full-dose anticoagulation 
(39%) is noteworthy. These numbers were thought 
to be either a result of potential drug interactions 
of oral anticoagulants or the critical clinical status 
or may be a combination of both. Furthermore, 
patients with AF received corticosteroids less 
frequently (31% vs. 47%, p = 0.02). There were no 
significant differences in the use of antiretroviral 
drugs or hydroxychloroquine in any of the groups.
No differences were noted regarding the 
number of days from admission to death, nor in 
the analysis of cumulative survival (Log rank 
p = 0.5 for cumulative survival of patients with AF 
vs. patients without AF; and Log rank p = 0.358 
for cumulative survival of patients with CAD vs. 
patients without CAD).
The prevalence of AF and CAD amongst 
those who died in the hospital wards in our center 
was lower than that reported in Italy by the Isti-
tuto Superiore di Sanità (30% CAD and 24.5% AF 
among the deceased) [6], despite the fact that the 
presented population is slightly older (81 ± 10 vs. 
79.5 ± 8.1 years). 
Although CAD or AF patients had more comor-
bidities and AF patients received less corticoste-
roids, their risk stratification on admission and the 
time from symptoms onset to death were similar.
The percentage of patients in the present 
study sample showed troponin elevation reached 
52%, much higher than the usual 8–12% amongst 
patients diagnosed with COVID-19 [7]. This higher 
frequency of troponin I elevation in the sample of de-
ceased patients (compared to the general COVID-19 
population with different outcomes), together with 
the absence of differences between the groups with 
and without CV comorbidity, seems to indicate that 
the development of myocardial insult depends fun-
damentally on the severity of the disease and not 
on the baseline characteristics of the patient, as it 
has been suggested in another series [8].
Due to the work overload caused by the pan-
demic, echocardiograms were not performed 
during the admission of most of the patients with 
myocardial injury defined as elevation of biomark-
ers. However, it would be interesting to know if 
this troponin elevation corresponded to impaired 
ventricular function, as had been described to be 
the case in sepsis [9].
Given the high prevalence of CV comorbidity 
in patients who develop severe forms of COVID-19, 
further research is needed on the management and 
prognosis of this population. Likewise, given the 
high incidence of myocardial insult amongst those 
with severe forms of the disease, the pathophysio-
logical substrate of myocardial damage and the 
potential benefit of cardioprotective strategies 
should be studied.
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